On October 14, 2025 Nusano, a physics company transforming the production of radioisotopes, and Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, reported the signing of a multi-isotope supply agreement to support Ariceum’s novel radiotherapeutic pipeline.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement gives Ariceum access to Nusano-produced radioisotopes, including actinium-225 (Ac-225) and lutetium-177 (Lu-177).
"Radiotherapeutics have the potential to redefine the standard of care in oncology," said Manuel Sturzbecher-Höhne, Chief Technology Officer of Ariceum Therapeutics. "This agreement further strengthens our ability to advance 225Ac-SSO110, which is currently being investigated in a Phase 1/2 trial in patients with extensive-stage small cell lung cancer and Merkel cell carcinoma. Reliable access to actinium-225 ensures we can deliver on our commitment to developing transformative therapies for patients facing these aggressive and underserved cancers."
The Nusano radioisotope production platform combines time-proven technology from universities and world-class research centers with the company’s patented particle acceleration technology. The result is the first significant advancement in radioisotope production in decades – a platform that’s smaller and more efficient than existing methods, and capable of the simultaneous manufacturing of up to 12 different radioisotopes.
"Nusano’s production capabilities are designed to stabilize supply chains and enable innovation," said Chris Lowe, CEO of Nusano. "Our scalable production allows us to work with drug developers from the earliest stages through commercial drug availability. We look forward to working with Ariceum on their current and future therapeutic candidates."
(Press release, Nusano, OCT 14, 2025, View Source [SID1234656644])